Larvol Delta - Climb-Bio-Announces-FDA-Fast-Track-Designation-for-Budoprutug-for-the-Treatment-of-Primary-Membranous-Nephropathy

budoprutug (TNT119) - Climb Bio

https://www.globenewswire.com/news-release/2026/04/07/3268966/0/en/Climb-Bio-Announces-FDA-Fast-Track-Designation-for-Budoprutug-for-the-Treatment-of-Primary-Membranous-Nephropathy.html

Apr 7, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next